Compare Merck & Co., Inc. (MRK) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs QUALCOMM, Inc. — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while QUALCOMM, Inc. trades at $173.05 (market cap $179.52B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | QCOM | |
|---|---|---|
Market Cap | $307.25B | $179.52B |
Sector | Health | Technology |
52-Week High | $129.52 | $251.10 |
52-Week Low | $77.60 | $124.07 |
Enterprise Value | $350.66B | $184.99B |
Dividend Yield | 2.73% | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
Qualcomm (QCOM) trades at $171.78, up 0.64% with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 54.8% gross margins and 22.31% net income margins, though revenue growth remains modest. Recent news highlights Qualcomm's AI and data center expansion efforts while facing smartphone market headwinds and increased competition from Nvidia's PC chip entry.
The stock presents a mixed outlook with attractive valuation (P/E 18.31) and analyst consensus target of $228.22 offering 33% upside potential. However, margin pressures and competitive threats from Nvidia's market expansion create near-term uncertainty. Institutional sentiment leans neutral with 50% hold ratings, suggesting cautious optimism about Qualcomm's diversification strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
